Bonomo RA Burd EM Conly J Limbago BM Poirel L Segre JA Westblade LF 2018 The dramatic increase in the prevalence and clinical impact of infections caused by bacteria producing carbapenemases is a global health concern. Carbapenemase production is especially problematic when encountered in members of the family Enterobacteriaceae. Due to their ability to readily spread and colonize patients in healthcare environments, preventing the transmission of these organisms is a major public health initiative and coordinated international effort are needed. Central to the treatment and control of carbapenemase-producing organisms (CPOs) are phenotypic (growth-/biochemical-dependent) and nucleic acid-based carbapenemase detection tests that identify carbapenemase activity directly or their associated molecular determinants. Importantly, bacterial isolates harboring carbapenemases are often resistant to multiple antibiotic classes, resulting in limited therapy options. Emerging agents, novel antibiotic combinations and treatment regimens offer promise for management of these infections. This review highlights our current understanding of CPOs with emphasis on their epidemiology, detection, treatment, and control. application/pdf https://sonar.ch/global/documents/80634 eng info:eu-repo/semantics/altIdentifier/doi/10.1093/cid/cix893 info:eu-repo/semantics/altIdentifier/pmid/29165604 info:eu-repo/semantics/openAccess Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. - 2018 Anti-Bacterial Agents Bacterial Proteins Carbapenem-Resistant Enterobacteriaceae Carbapenems Enterobacteriaceae Enterobacteriaceae Infections Global Health Humans Prevalence beta-Lactamases Carbapenemase-Producing Organisms: A Global Scourge. http://purl.org/coar/resource_type/c_6501